Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Inhaler Corticosteroid Device Market?

The market for inhaler corticosteroid devices has seen substantial growth in recent times. Its value is expected to rise from $15.75 billion in 2024 to $16.83 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. This growth during the historic period is likely due to factors such as increased spending on healthcare, a rise in the aging population, beneficial government policies, ongoing research and development activities, and high levels of disposable income.

In the coming years, the inhaler corticosteroid device market size is anticipated to experience substantial growth, expanding to $21.77 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. This growth during the projected period can be ascribed to increasing instances of respiratory illnesses, heightened awareness around respiratory health, significant funding in respiratory technologies, an amplified emphasis on health consciousness, and a growing prevalence of smoking addiction. Key trends to watch during this forecast period include the incorporation of advanced technologies, creation of combination treatments, digital inhalers that supply live data, progressive enhancements in inhaler technology, and the application of data analytics in inhaler devices.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp

Which Factor Is Shaping The Future Of The Inhaler Corticosteroid Device Market?

The growth of the inhaler corticosteroid device market is anticipated to be fueled by the escalating occurrence of respiratory diseases. Respiratory illnesses encompass a variety of conditions that impact the lungs and airways, obstructing proper and efficient breathing in individuals. The escalation in respiratory disorders can be linked to increasing air pollution, which exposes people to harmful particles that can damage the lungs and lead to chronic diseases such as asthma and bronchitis. Inhaler corticosteroid devices are employed to manage these diseases by providing anti-inflammatory drugs directly to the lungs, aiding in the reduction of inflammation and enhancement of breathing. For example, in June 2025, the UK-based government department, the Office for Health Improvement and Disparities, noted that in the financial year ending 2024, England had 854,922 emergency hospital admissions for respiratory disorders. This corresponded to a rate of 1,428 (with a range of 1,424 to 1,432) per 100,000 population, symbolizing a 7% increase from the previous year. Thus, with the rise in respiratory disease prevalence, the inhaler corticosteroid device market is experiencing a surge in growth.

What Is The Segment-Wise Breakdown Of The Inhaler Corticosteroid Device Market?

The inhaler corticosteroid device market covered in this report is segmented –

1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers

2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate

3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers

2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers

3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers

Which Trends Are Redefining The Future Landscape Of The Inhaler Corticosteroid Device Industry?

Leading corporations in the inhaler corticosteroid device industry are shifting their focus towards developing novel solutions. One such example is the reformation of rescue inhalers – a combination of albuterol and budesonide. These modified inhalers not only improve the effectiveness of treatment but also provide a merged, dual-action therapy in one device. A combination of albuterol and budesonide initiates a twin-action rescue inhaler which delivers a bronchodilator (albuterol) for immediate opening up of the airways and a corticosteroid (budesonide) to alleviate inflammation. This enables swift symptom relief and long-term management of asthma in one device. To illustrate, AstraZeneca PLC, a pharmaceutical firm based in the UK, launched the first-ever and only FDA-approved rescue inhaler that integrates albuterol and budesonide for adult asthma patients, named AIRSUPRA, in January 2024. This inhaler is designed for use as needed, facilitating relief from acute bronchoconstriction symptoms and simultaneously reducing inflammation in airways, hence mitigating the threat of serious asthma flare-ups. This new creation, combining a short-acting beta2-agonist (albuterol) and an inhaled corticosteroid (budesonide) in a single device was approved following clinical trials showing its superior prevention of asthma attacks compared to albuterol alone.

Which Companies Hold The Largest Market Share In The Inhaler Corticosteroid Device Sector?

Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH, Kos Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report

How Does Regional Performance Compare Across The Inhaler Corticosteroid Device Industry?

North America was the largest region in the inhaler corticosteroid device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25794&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model